Shilpa will deliver end-to-end services including CMC development, process scale-up, GMP clinical supply, and commercial manufacturing support
Veteran pharma leader brings 33+ years of experience to drive operational excellence in formulation business
New partnership combines Shilpa Biologicals’ development and manufacturing capabilities with SteinCares’ regional commercialization platform
Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections
This is the first approval of a prescription transdermal dosage Form in the European markets from this facility
The Unit is approved by major regulators like EMA, Europe; Health Canada, Anvisa, Brazil and TGA, Australia
OERIS offers extended antiemetic coverage through a single injection that effectively prevents both acute and delayed CINV for up to five days
Medico Remedies receives order worth US$ 1,781,000
NorUDCA is the first?in?class treatment for Non?alcoholic Fatty Liver Disease (NAFLD) in India
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
